Stoking the embers

Ember raises $34M from Third Rock to develop preclinical metabolic programs

Stoking the embers

Ember Therapeutics officially launched last week with a $34 million series A round from Third Rock Ventures to develop a pair of preclinical projects plucked from academia that could result in peripherally acting compounds to treat metabolic disorders, including obesity and

Read the full 436 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE